Dengue virus NS proteins inhibit RIG-I/MAVS signaling by blocking TBK1/IRF3 phosphorylation: Dengue virus serotype 1 NS4A is a unique interferon-regulating virulence determinant

mBio

Volumn 6, Issue 3, 2015, Pages 1-12

  Dalrymple, Nadine A ^a   Cimica, Velasco ^a   Mackow, Erich R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; I KAPPA B KINASE EPSILON; INTERFERON REGULATORY FACTOR 3; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2A; NONSTRUCTURAL PROTEIN 2B3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; PHOSPHOTRANSFERASE; RETINOIC ACID INDUCIBLE PROTEIN I; STING PROTEIN; TANK BINDING KINASE 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; INTERFERON; IRF3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, HUMAN; VIRAL PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DENGUE VIRUS 1; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANTAGONISTS AND INHIBITORS; DENGUE VIRUS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

DENGUE VIRUS; WEST NILE VIRUS;

DENGUE VIRUS; HOST-PATHOGEN INTERACTIONS; IMMUNE EVASION; INTERFERON REGULATORY FACTOR-3; INTERFERONS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84936935012     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00553-15     Document Type: Article

References (90)

1. Lindenbach BD, Murray CL, Thiel H-J, Rice CM. 2013. Flaviviridae. In Knipe DM, Howley PM (ed), Field's virology, vol 1, 6th ed, vol 1. Lippincott Williams & Wilkins, New York, NY.
2. Normile D. 2014. Tropical diseases. Dengue vaccine trial poses public health quandary. Science 345:367-368. http://dx.doi.org/10.1126/ science.345.6195.367.
3. Gubler DJ. 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 277:3-22, 71-73, 251-253. http:// dx.doi.org/10.1002/0470058005.ch2.
4. Guzman A, Istúriz RE. 2010. Update on the global spread of dengue. Int J Antimicrob Agents 36(Suppl 1):S40-S42. http://dx.doi.org/10.1016/ j.ijantimicag.2010.06.018.
5. Halstead SB. 2007. Dengue. Lancet 370:1644-1652. http://dx.doi.org/ 10.1016/S0140-6736(07)61687-0.
6. Halstead SB 2008. Pathophysiology, p 265-326. In Halstead SB (ed), Dengue, vol. 5. Imperial College Press, London, United Kingdom.
7. Martina BE, Koraka P, Osterhaus AD. 2009. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22:564-581. http://dx.doi.org/ 10.1128/CMR.00035-09.
8. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, SunW. 2011. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 204: 442-450. http://dx.doi.org/10.1093/infdis/jir279.
9. Ramakrishnan L, Pillai MR, Nair RR. 2015. Dengue vaccine development: strategies and challenges. Viral Immunol 28:76-84. http:// dx.doi.org/10.1089/vim.2014.0093.
10. Thomas SJ. 2014. Developing a dengue vaccine: progress and future challenges. Ann N Y Acad Sci 1323:140-159. http://dx.doi.org/10.1111/ nyas.12413.
11. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, Durbin A, Kirkpatrick B, Sette A. 2015. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 89:120-128. http://dx.doi.org/10.1128/JVI.02129-14.
12. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5:518-528. http://dx.doi.org/ 10.1038/nrmicro1690.
13. Wilder-Smith A, Macary P. 2014. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep 16:404. http://dx.doi.org/ 10.1007/s11908-014-0404-2.
14. Norrby R. 2014. Outlook for a dengue vaccine. Clin Microbiol Infect 20(Suppl 5):92-94. http://dx.doi.org/10.1111/1469-0691.12442.
15. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. http:// dx.doi.org/10.1016/S0092-8674(02)00660-8.
16. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS P a t h o g 6 : e 1 0 0 0 7 9 0 . h t t p : / / d x . d o i . o r g / 1 0 . 1 3 7 1 / journal.ppat.1000790.
17. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW, Lai JH. 2001. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 166:1499-1506. http://dx.doi.org/ 10.4049/jimmunol.166.3.1499.
18. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139. http://dx.doi.org/ 10.1016/j.chom.2010.01.004.
19. Basu A, Chaturvedi UC. 2008. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 53:287-299. http:// dx.doi.org/10.1111/j.1574-695X.2008.00420.x.
20. Dalrymple N, Mackow ER. 2011. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J Virol 85:9478-9485. http://dx.doi.org/10.1128/ JVI.05008-11.
21. Dalrymple NA, Mackow ER. 2012. Endothelial cells elicit immune enhancing responses to dengue virus infection. J Virol 86:6408-6415. http:// dx.doi.org/10.1128/JVI.00213-12.
22. Hiscott J. 2007. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 282:15325-15329. http://dx.doi.org/10.1074/ jbc.R700002200.
23. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4:491-496. http://dx.doi.org/10.1038/ni921.
24. Tu D, Zhu Z, Zhou AY, Yun CH, Lee KE, Toms AV, Li Y, Dunn GP, Chan E, Thai T, Yang S, Ficarro SB, Marto JA, Jeon H, Hahn WC, Barbie DA, Eck MJ. 2013. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 3:747-758. http://dx.doi.org/ 10.1016/j.celrep.2013.01.033.
25. Yoneyama M, Fujita T. 2007. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity. Cytokine Growth Factor Rev 18: 545-551. http://dx.doi.org/10.1016/j.cytogfr.2007.06.023.
26. Gleason CE, Ordureau A, Gourlay R, Arthur JS, Cohen P. 2011. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon beta. J Biol Chem 286:35663-35674. http://dx.doi.org/10.1074/jbc.M111.267567.
27. Ma X, Helgason E, Phung QT, Quan CL, Iyer RS, Lee MW, Bowman KK, Starovasnik MA, Dueber EC. 2012. Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad SciUSA 109:9378-9383. http://dx.doi.org/10.1073/pnas.1121552109.
28. Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J. 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol Biol 52:-17-28.
29. Pomerantz JL, Baltimore D. 1999. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 18:6694-6704. http://dx.doi.org/10.1093/emboj/ 18.23.6694.
30. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777. http://dx.doi.org/10.1038/nature03464.
31. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M, Jr, Früh K, Diamond MS. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 9:e1003118. http:// dx.doi.org/10.1371/journal.ppat.1003118.
32. Panne D, Maniatis T, Harrison SC. 2007. An atomic model of the interferon-beta enhanceosome. Cell 129:1111-1123. http://dx.doi.org/ 10.1016/j.cell.2007.05.019.
33. Kaukinen P, Sillanpää M, Nousiainen L, Melén K, Julkunen I. 2013. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J Med Virol 85:71-82. http:// dx.doi.org/10.1002/jmv.23442.
34. Liu WJ, Chen HB, Wang XJ, Huang H, Khromykh AA. 2004. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol 78:12225-12235. http:// dx.doi.org/10.1128/JVI.78.22.12225-12235.2004.
35. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 80:2396-2404. http:// dx.doi.org/10.1128/JVI.80.5.2396-2404.2006.
36. Baril M, Racine ME, Penin F, Lamarre D. 2009. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 83:1299-1311. http://dx.doi.org/10.1128/ JVI.01659-08.
37. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102: 17717-17722. http://dx.doi.org/10.1073/pnas.0508531102.
38. Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E, Hiscott J. 2006. Dissociation of a MAVS/ IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 80:6072-6083. http://dx.doi.org/10.1128/JVI.02495-05.
39. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M, Jr. 2006. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 103:6001-6006. http://dx.doi.org/10.1073/pnas.0601523103.
40. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167-1172. http://dx.doi.org/10.1038/nature04193.
41. Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M. 2013. Hepatitis C virus NS4B protein targets STING and abrogates RIGI-mediated type I interferon-dependent innate immunity. Hepatology 57: 46-58. http://dx.doi.org/10.1002/hep.26017.
42. Tasaka M, Sakamoto N, Itakura Y, Nakagawa M, Itsui Y, Sekine-Osajima Y, Nishimura-Sakurai Y, Chen CH, Yoneyama M, Fujita T, Wakita T, Maekawa S, Enomoto N, WatanabeM. 2007. Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardifinduced interferon response. J Gen Virol 88:3323-3333. http://dx.doi.org/ 10.1099/vir.0.83056-0.
43. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. 2000. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 74:7814-7823. http://dx.doi.org/10.1128/JVI.74.17.7814-7823.2000.
44. Diamond MS, Harris E. 2001. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289:297-311. http://dx.doi.org/10.1006/ viro.2001.1114.
45. Perry ST, Prestwood TR, Lada SM, Benedict CA, Shresta S. 2009. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J Virol 83:8276-8281. http://dx.doi.org/10.1128/JVI.00365-09.
46. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J Virol 78:2701-2710. http://dx.doi.org/ 10.1128/JVI.78.6.2701-2710.2004.
47. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, Block TM, Guo JT. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J Virol 84:8332-8341. http://dx.doi.org/10.1128/ JVI.02199-09.
48. Muñoz-Jordán JL, Laurent-Rolle M, Ashour J, Martínez-Sobrido L, Ashok M, Lipkin WI, García-Sastre A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 79: 8004-8013. http://dx.doi.org/10.1128/JVI.79.13.8004-8013.2005.
49. Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100:14333-14338. http://dx.doi.org/10.1073/pnas.2335168100.
50. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. 2010. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84:4845-4850. http:// dx.doi.org/10.1128/JVI.02514-09.
51. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A. 2010. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 84:9760-9774. http:// dx.doi.org/10.1128/JVI.01051-10.
52. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, Rodriguez-Madoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. 2012. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS P a t h o g 8 : e 1 0 0 2 9 3 4 . h t t p : / / d x . d o i . o r g / 1 0 . 1 3 7 1 / journal.ppat.1002934.
53. Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL, Lin YL. 2012. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog 8:e1002780. http://dx.doi.org/10.1371/ journal.ppat.1002780.
54. Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J. 2014. Inhibition of dengue and Chikungunya virus infections by RIG-I-mediated type I interferonindependent stimulation of the innate antiviral response. J Virol 88: 4180-4194. http://dx.doi.org/10.1128/JVI.03114-13.
55. Belgnaoui SM, Paz S, Samuel S, Goulet ML, Sun Q, Kikkert M, Iwai K, Dikic I, Hiscott J, Lin R. 2012. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 12:211-222. http:// dx.doi.org/10.1016/j.chom.2012.06.009.
56. Evans JD, Seeger C. 2007. Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling. J Virol 81:11809-11816. http://dx.doi.org/10.1128/JVI.00791-07.
57. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M. 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 79:5414-5420. http://dx.doi.org/ 10.1128/JVI.79.9.5414-5420.2005.
58. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M. 2009. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J Infect Dis 200: 1261-1270. http://dx.doi.org/10.1086/605847.
59. Morrison J, Aguirre S, Fernandez-Sesma A. 2012. Innate immunity evasion by dengue virus. Viruses 4:397-413. http://dx.doi.org/10.3390/ v4030397.
60. Munoz-Jordan JL, Bosch I. 2010. Modulation of the antiviral response by dengue virus, p 121-142. In Hanley KA, Weaver SC (ed), Frontiers in dengue virus research. Caister Academic Press, Norfolk, United Kingdom.
61. Suthar MS, Aguirre S, Fernandez-Sesma A. 2013. Innate immune sensing of flaviviruses. PLoS Pathog 9:e1003541. http://dx.doi.org/10.1371/ journal.ppat.1003541.
62. Ye J, Zhu B, Fu ZF, Chen H, Cao S. 2013. Immune evasion strategies of flaviviruses. Vaccine 31:461-471. http://dx.doi.org/10.1016/ j.vaccine.2012.11.015.
63. Ashour J, Laurent-Rolle M, Shi PY, García-Sastre A. 2009. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 83: 5408-5418. http://dx.doi.org/10.1128/JVI.02188-08.
64. Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 281:8854-8863. http://dx.doi.org/10.1074/jbc.M512697200.
65. Xie X, Gayen S, Kang C, Yuan Z, Shi PY. 2013. Membrane topology and function of dengue virus NS2A protein. J Virol 87:4609-4622. http:// dx.doi.org/10.1128/JVI.02424-12.
66. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. http:// dx.doi.org/10.1126/scisignal.2002521.
67. van Zuylen WJ, Doyon P, Clément JF, Khan KA, D'Ambrosio LM, Dô F, St-Amant-Verret M, Wissanji T, Emery G, Gingras AC, Meloche S, Servant MJ. 2012. Proteomic profiling of the TRAF3 interactome network reveals a new role for the ER-to-Golgi transport compartments in innate immunity. PLoS Pathog 8:e1002747. http://dx.doi.org/10.1371/ journal.ppat.1002747.
68. Maelfait J, Beyaert R. 2012. Emerging role of ubiquitination in antiviral RIG-I signaling. Microbiol Mol Biol Rev 76:33-45. http://dx.doi.org/ 10.1128/MMBR.05012-11.
69. Oudshoorn D, Versteeg GA, Kikkert M. 2012. Regulation of the innate immune system by ubiquitin and ubiquitin-like modifiers. Cytokine Growth Factor Rev 23:273-282. http://dx.doi.org/10.1016/ j.cytogfr.2012.08.003.
70. Wang L, Li S, Dorf ME. 2012. NEMO binds ubiquitinated TANKbinding kinase 1 (TBK1) to regulate innate immune responses to RNA viruses. PLoS One 7 :e43756. http://dx.doi.org/10.1371/ journal.pone.0043756.
71. Rajsbaum R, García-Sastre A. 2013. Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol 21:421-429. http://dx.doi.org/10.1016/j.tim.2013.06.006.
72. Goncalves A, Bürckstümmer T, Dixit E, Scheicher R, Górna MW, Karayel E, Sugar C, Stukalov A, Berg T, Kralovics R, Planyavsky M, Bennett KL, Colinge J, Superti-Furga G. 2011. Functional dissection of the TBK1 molecular network. PLoS One 6:e23971. http://dx.doi.org/ 10.1371/journal.pone.0023971.
73. Helgason E, Phung QT, Dueber EC. 2013. Recent insights into the complexity of TANK-binding kinase 1 signaling networks: the emerging role of cellular localization in the activation and substrate specificity of TBK1. FEBS L e t t 5 8 7 :1230-1 2 3 7 . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j.febslet.2013.01.059.
74. Larabi A, Devos JM, Ng SL, Nanao MH, Round A, Maniatis T, Panne D. 2013. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 3:734-746. http://dx.doi.org/10.1016/ j.celrep.2013.01.034.
75. Stern O, Hung YF, Valdau O, Yaffe Y, Harris E, Hoffmann S, Willbold D, Sklan EH. 2013. An N-terminal amphipathic helix in dengue virus nonstructural protein 4A mediates oligomerization and is essential for replication. J Virol 87:4080-4085. http://dx.doi.org/10.1128/JVI.01900-12.
76. Guzman MG, Kouri G. 2003. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol 27:1-13. http:// dx.doi.org/10.1016/S1386-6532(03)00010-6.
77. Ong A, Sandar M, Chen MI, Sin LY. 2007. Fatal dengue hemorrhagic fever in adults during a dengue epidemic in Singapore. Int J Infect Dis 11:263-267. http://dx.doi.org/10.1016/j.ijid.2006.02.012.
78. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74:4957-4966. http://dx.doi.org/10.1128/ JVI.74.11.4957-4966.2000.
79. Chen HW, King K, Tu J, Sanchez M, Luster AD, Shresta S. 2013. The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J Immunol 191:4194-4201. http://dx.doi.org/10.4049/ jimmunol.1300799.
80. Lai CJ, Zhao BT, Hori H, BrayM. 1991. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A 88:5139-5143. http://dx.doi.org/10.1073/pnas.88.12.5139.
81. Mackow E, Makino Y, Zhao BT, Zhang YM, Markoff L, Buckler-White A, Guiler M, Chanock R, Lai CJ. 1987. The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins. Virology 159:217-228. http://dx.doi.org/10.1016/0042-6822(87)90458-2.
82. Polo S, Ketner G, Levis R, Falgout B. 1997. Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast. J Virol 71:5366-5374.
83. Puri B, Polo S, Hayes CG, Falgout B. 2000. Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain. Virus Genes 20:57-63. http://dx.doi.org/10.1023/A:1008160123754.
84. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, Kaufman PD. 2009. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4:e6529. http://dx.doi.org/10.1371/journal.pone.0006529.
85. Sumpter R, Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79:2689-2699. http://dx.doi.org/10.1128/ JVI.79.5.2689-2699.2005.
86. Cárdenas WB, Loo YM, Gale M, Jr, Hartman AL, Kimberlin CR, Martínez-Sobrido L, Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80:5168-5178. http:// dx.doi.org/10.1128/JVI.02199-05.
87. Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 18:2986-2996.
88. Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, Yamamoto M, Akira S, Fitzgerald KA. 2005. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 175:5260-5268. http://dx.doi.org/ 10.4049/jimmunol.175.8.5260.
89. Cimica V, Dalrymple NA, Roth E, Nasonov A, Mackow ER. 2014. An innate immunity-regulating virulence determinant is uniquely encoded by the Andes virus nucleocapsid protein. mBio 5(1):e01088-13. http:// dx.doi.org/10.1128/mBio.01088-13.
90. Matthys VS, Cimica V, Dalrymple NA, Glennon NB, Bianco C, Mackow ER. 2014. Hantavirus GnT elements mediate TRAF3 binding and inhibit RIG-I/TBK1-directed beta interferon transcription by blocking IRF3 phosphorylation. J Virol 88:2246-2259. http://dx.doi.org/10.1128/ JVI.02647-13.